
Description: Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022

According to the meticulous report Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022, the global PGx market is expected to grow over $14.85 billion by 2022. An analyst at BIS Research states, “Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market.”

Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created a platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market yet, however, the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others. The patients benefit indirectly from these regulations as it saves time and cuts down cost as the patients get the required treatment for the specific disease.

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players , type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter's Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it.

The answers to the following key questions can be found in the report:
What are the major market drivers, challenges and opportunities of the PGx market and their use cases?
What are the key trends and developments in the PGx market for genetic disease management?
What are the key developmental strategies in different therapeutics across all regions?
What are different types of PGx drugs and tests which are available in the market?
How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?
Which geographical region will lead the global PGx market by the end of the forecast period?
Which different technologies are used to develop PGx solutions?
Who are the key players in the PGx market?
What are the government regulations for different PGx solutions?
What are different types of therapeutics in PGx market and which type of PGx product used in their treatment?
What is the different used case scenarios considered under different therapeutic applications?
What are the PGx market trends and key developments in different geographical regions?

The research deals with various aspects of the PGx market such as factors driving the market, its threats that can possibly slow down the market growth and the current growth opportunities that are going to shape the market expansion of PGx solutions. The research incorporates Porter's Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of PGx market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global PGx market is subjected to, including the estimation of the industry's growth in terms of production and revenue. The report includes the profiles of major players in the PGx market that allows the readers to gain an insight into the various industry trends.

Contents:

1. Report Overview
   1.1. Report Scope
      1.1.1. Report Coverage
      1.1.2. Assumptions And Limitations
      1.1.3. Market Classification & Segmentation
   1.2. Research Methodology
      1.2.1. Data Points Considered For Market Size Estimation
      1.2.2. Key Data Point Sources
         1.2.2.1. Key Data Points From Primary Sources
         1.2.2.2. Key Data Points From Secondary Sources
      1.2.3. Data Triangulation
      1.2.4. Top-Down Approach
      1.2.5. Bottom-Up Approach
   1.3. Report Description

2. Executive Summary
   2.1. Global Market Scenario

3. Market Overview
   3.1. Introduction
   3.2. Pharmacogenomics: Mechanism Of Action
   3.3. Role Of Companion Diagnostics In Pgx
   3.4. Role Of Biomarkers In Pgx
   3.5. Role Of Molecular Diagnostics In Pgx
   3.6. Benefits Of Pgx
   3.7. End-Use Applications Of Pgx
   3.8. Market Dynamics
      3.8.1. Market Drivers
      3.8.2. Market Challenges
      3.8.3. Market Opportunities

4. Competitive Insights
   4.1. Key Market Developments & Strategies
      4.1.1. Competitive Landscape Of Some Of The Key Players
      4.1.2. Partnerships, Joint Ventures And Collaborations
4.1.2.1. Key Insights
4.1.2.2. Recent Partnerships, Joint Ventures And Collaborations
4.1.3. Product Launch And Developments
4.1.3.1. Key Insights
4.1.3.2. Recent Product Launch And Developments
4.1.4. Patents, Licensing, Certification And Approvals
4.1.4.1. Key Insights
4.1.4.2. Recent Patents, Licensing, Certification And Approvals
4.1.5. Mergers And Acquisitions
4.1.5.1. Key Insights
4.1.5.2. Recent Mergers And Acquisitions
4.1.6. Business Contracts And Business Expansions
4.1.6.1. Key Insights
4.1.6.2. Recent Business Contracts And Business Expansions
4.1.7. Other Strategies
4.1.7.1. Key Insights
4.1.7.2. Recent Developments Of Other Strategies
4.1.7.2.1. Porter's Five Forces Analysis
4.1.7.2.1.1. Threat Of Substitutes
4.1.7.2.1.2. Threat Of New Entrants
4.1.7.2.1.3. Bargaining Power Of Buyers
4.1.7.2.1.4. Bargaining Power Of Suppliers
4.1.7.2.1.5. Intensity Of Competitive Rivalry
5. Industry Analysis
5.1. Patent Analysis
5.1.1. Some Of The Key Players
5.1.2. Others (University/Hospital/Person)
5.2. Regulations, Consortiums, Certifications, & Standards
5.2.1. Regulatory Bodies
5.2.2. Examples Of Some Common Acts Certification
5.3. Value Chain Analysis
6. Global Pharmacogenomics Market By Technology
6.1. Market Segmentation By Technology
6.2. Microarray
6.2.1. Introduction
6.2.2. Microarray: Types, Applications & Key Players
6.2.3. Microarray: Market Dynamics & Recent Developments
6.3. Sequencing
6.3.1. Introduction
6.3.2. Sequencing: Market Dynamics, Applications & Key Players
6.3.3. Types Of Sequencing Technologies
6.3.3.1. Sanger Sequencing
6.3.3.2. Pyrosequencing
6.3.3.3. Next-Gen Sequencing (Ngs)
6.3.3.3.1. Next-Gen Sequencing (Ngs) Applications & Key Players
6.3.3.3.2. Next-Gen Sequencing (Ngs) Recent Developments
6.4. Polymerase Chain Reaction (Pcr)
6.4.1. Introduction
6.4.2. Pcr Types
6.4.3. Pcr: Market Dynamics, Applications & Key Players
6.5. Other Technologies
6.5.1. Mass Spectrometry
6.5.2. Electrophoresis
7. Global Pharmacogenomics Market By Ecosystem Players
7.1. Pgx Ecosystem Players: Overview
7.2. Market Segmentation By Ecosystem Players
7.2.1. Market Insights & Statistics
7.3. Diagnostic Test Companies
7.3.1. Introduction
7.3.2. Market Statistics
9.3.5.1. The U.S.: Market Statistics
9.3.5.2. The U.S.: Key Insights
9.3.6. Canada
9.3.7. Recent Key Developments
9.4. Europe
9.4.1. Market Scope
9.4.2. Europe: Market Insights & Statistics
9.4.3. European Market Dynamics
9.4.4. Key Regulatory Bodies & Associations
9.4.5. The U.K.
9.4.6. Germany
9.4.7. Recent Key Developments
9.5. Asia-Pacific (Apac)
9.5.1. Market Scope
9.5.2. Apac: Market Insights & Statistics
9.5.3. Apac Market Dynamics
9.5.4. China
9.5.5. Japan
9.5.6. India
9.5.7. Recent Key Developments
9.6. Rest Of The World (Row)
9.6.2. Middle East
9.6.3. South America
9.6.4. Africa
9.6.5. Recent Key Development

10. Company Overview
10.1. Abbott Laboratories
10.1.1. Overview
10.1.2. Financials
10.1.3. Financial Summary
10.1.4. Key Developments
10.1.5. Swot Analysis
10.2. Affymetrix, Inc.
10.2.1. Overview
10.2.2. Financials
10.2.3. Financial Summary
10.2.4. Key Developments
10.2.5. Swot Analysis
10.3. Assurex Health, Inc.
10.3.1. Overview
10.3.2. Key Developments
10.3.3. Swot Analysis
10.4. Astrazeneca
10.4.1. Overview
10.4.2. Financials
10.4.3. Financial Summary
10.4.4. Key Developments
10.4.5. Swot Analysis
10.5. Illumina, Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Financial Summary
10.5.4. Key Developments
10.5.5. Swot Analysis
10.6. Laboratory Corporation Of America Holdings
10.6.1. Overview
10.6.2. Financials & Financial Summary
10.6.3. Key Developments
10.6.4. Swot Analysis
10.7. Myriad Genetics, Inc.
10.7.1. Overview
List Of Tables
Competitive Landscape: Some Of The Key Players
Recent Partnerships, Joint Ventures And Collaborations
Recent Product Launch And Developments
Recent Patents, Licensing, Certification And Approvals
Recent Mergers And Acquisitions
Recent Business Contracts And Business Expansions
Recent Developments Of Other Strategies
Patent Analysis Of Some Key Players
Patent Analysis Of Some University/Hospital/Person
Microarray- Recent Key Developments
Ngs- Recent Key Developments
Difference Between Real Time & Digital Pcr
Diagnostic Test Companies- Recent Key Developments
Example Of Some Pharmacogenomic Drugs
Pharmaceuticals Companies- Recent Key Developments
Service Providers- Recent Key Developments
Cancer- Examples Of Some Drugs
Cancer- Examples Of Some Tests
Oncology- Recent Key Developments
Cvd- Examples Of Some Drugs
Cvd- Examples Of Some Tests
Cns- Examples Of Some Drugs
Cns- Examples Of Some Tests
Infectious Diseases- Examples Of Some Drugs
Other Diseases- Examples Of Some Drugs
North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
North American Pharmacogenomics Market Recent Key Developments
European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
European Pgx Market Recent Key Developments
Apac Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
Apac Pharmacogenomics Market Recent Key Developments
Row Pharmacogenomics Market, By Sub-Region, 2015-2022
Row Recent Key Development
Abbott Laboratories, Inc. Recent Developments
Affymetrix, Inc. Recent Developments
Assurex Health, Inc. Recent Developments
Astrazeneca Recent Developments
Illumina, Inc. Recent Developments
Laboratory Corporation Of America Holding Recent Developments
Myriad Genetics Recent Developments
Pfizer, Inc. Recent Developments
Qiagen Recent Developments
Roche Holding Recent Developments
Teva Pharmaceutical Industries Ltd. Recent Developments
Thermo Fisher, Inc. Recent Developments
Transgenomic, Inc. Recent Developments

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3651979/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3651979/
Office Code: SCBRFF36

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 3799</td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3799</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 4099 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 5650</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 5650</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 6650</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 6650</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>___________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>___________________________</td>
</tr>
<tr>
<td>City:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>___________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>___________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World